Scoring treatment response in patients with relapsing multiple sclerosis
- 25 September 2012
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 19 (5) , 605-612
Abstract
Background: We employed clinical and magnetic resonance imaging (MRI) measures in combination, to assess patient responses to interferon in multiple sclerosis. Objective: To optimize and validate a scoring system able to discriminate responses to interferon treatment in patients with relapsing–remitting multiple sclerosis (RRMS). Methods: Our analysis included two large, independent datasets of RRMS patients who were treated with interferons that included 4-year follow-up data. The first dataset (“training set”) comprised of 373 RRMS patients from a randomized clinical trial of subcutaneous interferon beta-1a. The second (“validation set”) included an observational cohort of 222 RRMS patients treated with different interferons. The new scoring system, a modified version of that previously proposed by Rio et al., was first tested on the training set, then validated using the validation set. The association between disability progression and risk group, as defined by the score, was evaluated by Kaplan Meier survival curves and Cox regression, and quantified by hazard ratios (HRs). Results: The score (0–3) was based on the number of new T2 lesions (>5) and clinical relapses (0,1 or 2) during the first year of therapy. The risk of disability progression increased with higher scores. In the validation set, patients with score of 0 showed a 3-year progression probability of 24%, while those with a score of 1 increased to 33% (HR = 1.56; p = 0.13), and those with score greater than or equal to 2 increased to 65% (HR = 4.60; p < 0.001). Conclusions: We report development of a simple, quantitative and complementary tool for predicting responses in interferon-treated patients that could help clinicians make treatment decisions.Keywords
This publication has 13 references indexed in Scilit:
- Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosisNeurology, 2011
- Multiple sclerosis: current treatment algorithmsCurrent Opinion in Neurology, 2011
- One‐year MRI scan predicts clinical response to interferon beta in multiple sclerosisEuropean Journal of Neurology, 2009
- Measures in the first year of therapy predict the response to interferon β in MSMultiple Sclerosis Journal, 2009
- MRI activity and neutralising antibody as predictors of response to interferon treatment in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patientsAnnals of Neurology, 2006
- Predictors of long–term clinical response to interferon beta therapy in relapsing multiple sclerosisJournal of Neurology, 2005
- Defining interferon β response status in multiple sclerosis patientsAnnals of Neurology, 2004
- Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 1998
- Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trialNeurology, 1990